Patients with melanoma or glioblastoma receiving personalized neoantigen vaccines appear to favor CD4+ over CD8+ T-cell responses against the immunizing peptides, even though these were predicted and prioritized using HLA-I binding algorithms (21, 22). Here, CD4 is linked to melanoma.